Calcium channel blockers: of action and peculiarities clinical usage.

Prof. A.G. Oparin, prof. A.A. Oparin, PHD E.L. Ycovenko. Kharkiv Medical Academy of Postgraduate Education.

The article presents the latest data of the mechanisms of action and classification of calcium antagonists, the features of the usage of calcium channel blockers in isolated cardiac and vascular disease and in case of comorbid pathology of internal diseases, general effects and side- effects of calcium antagonists, as well as the characteristics of their interaction with other drugs.

Key Words: calcium antagonists, hypertension, arrhythmias, ischemic heart disease.

Oparin AG, Oparin AA, Ycovenko EL. [Calcium channel blockers: of action and peculiarities clinical usage]. Shidnoevr. z. vnutr. simejnoi med. 2014;1:51-56. Russian.

http://dx.doi.org/10.15407/internalmed2014.01.005

Download.PDF

Test «Calcium channel blockers: of action and peculiarities clinical usage».

1. Barsukov AV, Vasileva IA, Karimova AM, authors; Barsukov AV, editor. Arterialnaia gipotenziia (aktualnye voprosy diagnostiki i profilaktiki i lecheniia). [Arterial hypotension (actual questions of diagnostics and prevention and treatment)]. SPb.: ELBI. 2012; 144 Russian

2. Vertkin AL. Lechenie arterialnoi gipertenzii: kombinatsiia lekarstvennykh sredstv i kombinirovannye preparaty. [Treatment of arterial hypertension: combination of medications and combined preparations]. Russkii meditsinskii zhurnal. 2010; 18: 708—710. Russian

3. Moiseev VS, Martynov AI, authors; Mukhin NA, editor. Vnutrennie bolezni. [Internal medicine]. In: 2 ed. 2 – ed., reworked and enlarged. M.: GEOTAR-Media, 2012. 581 p. Russian

4. Moiseev VS, editor. Vnutrennie bolezni: uchebnik s kompakt-diskom. In 2 v. [Internal diseases: textbook with compact-disk]. In: 3 ed., reworked and enlarged. M.: GEOTAR-Media; 2012; 2: 896. Russian

5. Chumaka VT, Maltseva VI, Morozova AM, Parii VD, Stepanenko AV, Dumenko TM authors; Blikhar VI, editor. Derzhavnyi formuliar likarskykh zasobiv. [State form of medications]. K., 2012; 3. Electronic version. Ukrainian

6. Dovidnyk likarskykh zasobiv. [Medicines Handbook] (edition 5, stage on 01.05.2011r.). Electronic version. Ukrainian

7. Evdokimov AG, Topolianskii VD, authors. Bolezni arterii i ven. [Arterial and venous diseases]. M.: MEDpress — inform, 2012. 256 p. Russian

8. Karpov IA, Sorokin DV, authors; Karpov IA, editor. Stabilnaia ishemicheskaia bolezn serdtsa: strategiia i taktika lecheniia. [Stable ishemic heart disease: strategy and tactics of treatment]. 3-ed., reworked and enlarged. M.: MIA, 2012. 272 p. Russian

9. Kovalenko VM, Lutai MI, authors. Sertsevo-sudynni zakhvoriuvannia: Rekomendatsii z diahnostyky, profilaktyky ta likuvannia. [Cardiovascular diseases: recommendations for diagnostics, prevention and treatment]. K.: MORION, 2011. 408 p. Ukrainian

10. Oparin AA, Oparin AG, Korenovskii IP, Lavrova NV, authors; Oparin AA, editor. Algoritmy EKG-diagnostki v klinike vnutrennikh boleznei: metod. posob. [Algorhithms of ECG diagnostics in clinics of internal diseases: methodical tutorial]. Kharkov: Fakt, 2010. 80 p. Russian

11. Oparin AA, Oparin AG, Korenovskii IP, Lavrova NV, authors; Oparin AA, editor. Lektsii po klinicheskoi farmakologii. [Lectures on clinical pharmacology]. Kharkov: Fakt, 2011. 254 p. Russian

12. Oparin AG, Oparin AA, Lavrova NV, Korenovskii IP, authors; Oparin AA, editor. Klinicheskaia farmakologiia v kardiologii. [Clinical pharmacology in cardiology]— Kharkov: Fakt; 2013: 80 p. Russian

13. Montalescot G, Sechtem U [2013 ESC guidelines on the management of stable coronary artery disease]. Eur. Heart I. doi:10.1093/eurhearti/ent296. English

14. Palaniswamy C, Aronow WS. [Treatment of stable angina pectoris]. Am. I. Ther. 2011;18(5): 138— 152. English http://dx.doi.org/10.1097/MJT.0b013e3181f2ab9d

15. Henderson RF, O’Flynn N. [Management of stable angina: summary of NICE guidance]. Heart. 2012; 98: 500—507. English http://dx.doi.org/10.1136/heartjnl-2011-301436

16. Pepine CI, Douglas PS. [Rethinking stable ischemic heart disease. Is this the beginning of a new era?]. IACC. 2012; 60(11): 957—959. English

17. Opie LY, Horowitz ID. [Nitrates and newer anti-anginals]. Drugs for the Heart. Elsevier. 2012; 8. English

18. Bangalore S, Steg G, Deedwania P. [Beta-Bloker use and clinical outcomes in stable outpatients with and without coronary artery disease]. IAMA; 308(13): 1340—1349. English

19. Tendera M, Borer IS, Tardif IC. [Efficacy of I (f) inhibition with ivabradine in different subpopulations with stable angina pectoris]. Cardiol. 2009;114(2): 116—125. English http://dx.doi.org/10.1159/000219938

20. Tardif IC, Ponikoski P, Kahan T. [Efficacy of the I (f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo- controlled trial]. Eur. Heart I. 2009; 30: 540—548. English http://dx.doi.org/10.1093/eurheartj/ehn571

21. Fox K, Horinaka S. [Use of Nicorandil in cardiovascular disease and its optimization] Drugs. 2011; 71(9): 1105—1119. English http://dx.doi.org/10.2165/11592300-000000000-00000

22. Izumiya Y, Koiima S, Araki S. [Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris]. Atherosclerosis. 2011; 214: 415—421. English http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.032

23. Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral salution), http://www.ema.europa.eu/ docs/en_GB/document_library/Referrals_document/ Trimetazidine_31/WC500129195.pdf (9 March 2012).

24. Stone PY. [The Anti-Ischemic Mechanism of Action of Ranolazine in Stable Ischemic Heart Disease]. IACC. 2010; 56(12): 934—942. English

25. Monaco D, Sestito A. [The patient with chronic ischemic heart disease. Role of ranolazine in management of stable angina]. Eur. Rev. Med. Pharmacol. Sci. 2012; 16(12): 1611—1636. English

26. Wilson SR, Scirica BM, Braunwald E. [Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLINTIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Segment Elevation Acute Coronary Syndromes) 36 Trial]. I. Am. Coll. Cardiol. 2009; 53(17): 1510—1516. English http://dx.doi.org/10.1016/j.jacc.2009.01.037

27. Noman A, Ang DS, Ogston S. [Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial]. Lancet. 2010; 375: 2161—2167. English http://dx.doi.org/10.1016/S0140-6736(10)60391-1